Clinical Trials
21 trialsNCT06806033 2026-05-26
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Phase 2 Recruiting
NCT06867536 2026-05-15
GLOHRT-01
Huazhong University of Science and Technology
Phase 2 Recruiting
NCT05896163 2026-05-06
MAPtivate-6
Pfizer
Phase 1/2 Terminated
NCT07200375 2026-05-04
GlofitReal
Hoffmann-La Roche
Recruiting
NCT06765317 2026-04-30
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06050694 2026-04-24
GRAIL
University Health Network, Toronto
Phase 2 Recruiting
NCT07528352 2026-04-17
REBEL
University of Utah
Phase 1 Not yet recruiting
NCT05798156 2026-04-08
R-Pola-Glo
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Active not recruiting
NCT04408638 2026-04-07
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT07502872 2026-03-31
TPG
Brown University
Phase 2 Not yet recruiting
NCT07480850 2026-03-18
Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Active not recruiting
NCT05800366 2026-03-05
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT04231877 2026-03-03
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
University of Washington
Phase 1 Recruiting
NCT05364424 2025-12-01
A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma
Hoffmann-La Roche
Phase 1 Completed
NCT06665217 2025-08-14
G-Pola-ZLP in Diffuse Large B-Cell Lymphoma
Navy General Hospital, Beijing
Phase 2 Not yet recruiting
NCT06651853 2025-07-23
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT07012980 2025-06-10
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT06552572 2025-05-21
Glory
Samsung Medical Center
Phase 2 Active not recruiting
NCT05335018 2024-12-16
GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma
Seoul National University Hospital
Phase 2 Active not recruiting
NCT06656234 2024-10-24
The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
Ruijin Hospital
Not yet recruiting
NCT04914741 2024-08-12
COALITION
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Active not recruiting